How much will these cost? I'd love some immediately. I'm starting to need reading glasses and it is really disruptive to my whole life, I do lots of hobbies that need close up vision and never knew what life was like not having it.
Edit:
"During the investor call, Lenz executives outlined the cost of VIZZ. A monthly, 25-pack will cost $79. A 3-month pack from the e-pharmacy will cost $198 ($66 per month). Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025."
If you're mid-40s (which is the threshold ago where I am), and can afford the up front cost, consider IOL implants. Life changing (for me). (and re: costs, these drops are going to set you back $1000 a year as well, so after 7/8 years implants would be 'cheaper').
"Gentle" or not, is this actually safe for long-term use? Your pupil dilates in indoor light for a reason, I'm not sure if it's a good idea to fight that. You'd be better off just increasing ambient light levels to match sunlight.
I'd say there's a reason we've moved to daily contact lenses over re-usable ones, conveniently in a ~monthly~ 28-day pack!
There's obviously bound to be 'medical' and comfort reasons over disposable ones beyond the disposable society, but the cynic in me can't help but feel that research into longer-lasting more-comfortable reusable contacts would be taken through to market in preference to a more profitable cheaper-made daily product.
> The FDA approval comes based on trial data submitted by the pharmaceutical company, so it's worth noting that published peer-reviewed reports are yet to be published. Peer-reviewed publications often follow regulatory approvals, not precede them, which is common in the field of ophthalmology and dermatology.
Does anyone know the reason that data is published after approval rather than before? Seems illogical at face value, but I'm obviously missing something.
Short answer: FDA is totally toothless these days after decades of industry lobbying and Republican budget cuts. The industry has decided how they want things to work.
>Short answer: FDA is totally toothless these days after decades of industry lobbying and Republican budget cuts.
The funny thing about short answers is that they're often partly or wholly full of shit and don't describe the underlying reality. For example, see how different things get when you look at actual information instead of pulling ideological talking points out of your ass without knowing what the hell is even the case? (A common thing on this site among so many self-described highly intelligent people)
This is the FDA's actual funding history over the last 3 decades (page 6 of the PDF), showing a steadily increasing budget across both Republican and Democrat admins. Curiously, some of its bigger budget increases coincided with the first Trump administration even. https://sgp.fas.org/crs/misc/R44576.pdf
It’s because the publishing process takes more time than the FDA review process.
Once the pivotal trial reads out, companies usually submit within a month or two to the FDA. Much of the submission dossier (trial design, product description) can be written ahead of time, so it’s really the results that need to be drafted.
The FDA can approve in as little as 3-4 months for an accelerated approval, but it can take up to 12 months.
Compare that with a paper being written and reviewed across multiple authors (3-6 months if you’re lucky), then submitting to multiple journals for review and feedback (6 months), then final submission and peer review (1-2 months), then any additional edits (1 month), then final slating for publication after article is type set, all figures are sized, article laid out and final version (1-2 months).
So all in the FDA takes less time (3-12 months) than publishing (12-17 months).
Related question: When I looked into LASIK/SMILE recently, they said that after onset of presbyopia, they now routinely recommend "monovision", that is, regulate one of your eyes to 0 diopters, but the other to mild myopia of about -1 diopter. Then you look at far things with the former, and near things with the latter. Good old stereo vision is somewhat impacted, but not too badly apparently.
Anyone got experience/comments on that? (Presumably one could replicate it with contact lenses, in particular.)
It’s mentioned in the article, but there’s been a product on the market already for almost 5 years that does the same thing, with the same mechanism of action. That product, Vuity, has not been popular. The article makes it seem like the reason for Vuity’s lackluster performance is the incidence of side effects but I think it’s just not something people want to pay money for long term.
The drops work by selectively acting on the muscles that control pupil size, constricting the eyes’ aperture. As anyone who knows photography is aware, this increases the depth of field (a larger range of distances from the eye will be approximately in focus). Of course this also reduces the brightness on the retina, so things will be darker, an effect confirmed by the linked FDA data. In that data it’s claimed that the perceived dimness is “temporary”; I guess because of accommodation that kicks in after a while. So this is like increasing your f-stop and your ISO.
This drug is for presbyopia (near things blurry) not myopia (far things blurry) but as these threads tend to discuss both, I will share something I read on HN many years ago that reversed my myopia: near-far focusing while outdoors. Just focus on something at >50 foot distance, focus on your finger right in front of your eye, near, far, near, far focusing just a few times. This completely reversed my early-stage myopia and my eyesight has been 20/20 for years since.
27 comments
[ 3.9 ms ] story [ 52.3 ms ] threadEdit:
"During the investor call, Lenz executives outlined the cost of VIZZ. A monthly, 25-pack will cost $79. A 3-month pack from the e-pharmacy will cost $198 ($66 per month). Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025."
Does this mean you could replicate the effect with brighter lighting? I was hoping for something that would actually make the lens more flexible.
"Gentle" or not, is this actually safe for long-term use? Your pupil dilates in indoor light for a reason, I'm not sure if it's a good idea to fight that. You'd be better off just increasing ambient light levels to match sunlight.
There's obviously bound to be 'medical' and comfort reasons over disposable ones beyond the disposable society, but the cynic in me can't help but feel that research into longer-lasting more-comfortable reusable contacts would be taken through to market in preference to a more profitable cheaper-made daily product.
Does anyone know the reason that data is published after approval rather than before? Seems illogical at face value, but I'm obviously missing something.
The funny thing about short answers is that they're often partly or wholly full of shit and don't describe the underlying reality. For example, see how different things get when you look at actual information instead of pulling ideological talking points out of your ass without knowing what the hell is even the case? (A common thing on this site among so many self-described highly intelligent people)
This is the FDA's actual funding history over the last 3 decades (page 6 of the PDF), showing a steadily increasing budget across both Republican and Democrat admins. Curiously, some of its bigger budget increases coincided with the first Trump administration even. https://sgp.fas.org/crs/misc/R44576.pdf
Once the pivotal trial reads out, companies usually submit within a month or two to the FDA. Much of the submission dossier (trial design, product description) can be written ahead of time, so it’s really the results that need to be drafted.
The FDA can approve in as little as 3-4 months for an accelerated approval, but it can take up to 12 months.
Compare that with a paper being written and reviewed across multiple authors (3-6 months if you’re lucky), then submitting to multiple journals for review and feedback (6 months), then final submission and peer review (1-2 months), then any additional edits (1 month), then final slating for publication after article is type set, all figures are sized, article laid out and final version (1-2 months).
So all in the FDA takes less time (3-12 months) than publishing (12-17 months).
Anyone got experience/comments on that? (Presumably one could replicate it with contact lenses, in particular.)
I (and others) make this comment on HN from time to time: https://news.ycombinator.com/item?id=38794682 - hopefully it helps others.